SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy

SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy

Live virus neutralization is the gold standard to investigate immunity. This prospective observational study aimed to determine the magnitude of response against the original B.1 lineage and against the BA.5 lineage six months after the third BNT162b2 mRNA vaccine dose in patients with HIV infection...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccines (Basel) 2023-04, Vol.11 (4), p.871
Hauptverfasser: Vicenti, Ilaria, Basso, Monica, Pirola, Nicole, Bragato, Beatrice, Rossi, Maria Cristina, Giobbia, Mario, Pascoli, Susanna, Vinci, Antonio, Caputo, Sara, Varasi, Ilenia, Biba, Camilla, Fiaschi, Lia, Zazzi, Maurizio, Parisi, Saverio Giuseppe
Format: Artikel
Sprache:eng
Schlagworte:
Amino acids
Antibodies
Antiretroviral agents
Antiretroviral drugs
Antiretroviral therapy
B.1 lineage
BA.5 lineage
BNT162b2 mRNA vaccine
Brief Report
CD4 antigen
Coronaviruses
COVID-19
COVID-19 vaccines
Drug dosages
Drug therapy
Effectiveness
HIV
HIV patients
Human immunodeficiency virus
Identification and classification
Infections
Lymphocytes
Lymphocytes T
mRNA
mRNA vaccines
Mutation
Neutralization
Neutralizing
Observational studies
Outliers (statistics)
SARS-CoV-2
Sensitivity analysis
Severe acute respiratory syndrome coronavirus 2
Software
Statistical analysis
third dose
Vaccine efficacy
Vaccines
Viral antibodies
Viral diseases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Live virus neutralization is the gold standard to investigate immunity. This prospective observational study aimed to determine the magnitude of response against the original B.1 lineage and against the BA.5 lineage six months after the third BNT162b2 mRNA vaccine dose in patients with HIV infection on successful antiretroviral treatment and no previous SARS-CoV-2 infection. A total of 100 subjects (M/F 83/17, median age 54 years) were included in the analysis: 95 had plasma HIV RNA
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines11040871